Download PDF
Kardiologie up2date 2005; 1(3): 200-208
DOI: 10.1055/s-2005-870395
Hotline - Koronare Herzerkrankung und Arteriosklerose
© Georg Thieme Verlag KG Stuttgart · New York

Plättchenhemmung als Therapieprinzip der Primär- und Sekundärprophylaxe bei koronarer Herzkrankheit

Felix  Post
Further Information

Publication History

Publication Date:
09 September 2005 (online)

Also available at
    Permissions and Reprints All articles of this category

Einleitung

Die koronare Herzerkrankung (KHK) ist die Manifestation der Atherosklerose an den Herzkranzarterien. In den Frühstadien der Erkrankung sind in der Regel keine klinischen Symptome vorhanden, obwohl die endotheliale Funktion bereits gestört und Lipide in der Gefäßwand eingelagert sind. Bei Plaquerupturen kommt es durch rasche Aktivierung von Thrombozyten zu akuten Ischämiesyndromen. Hier ist der Hauptansatzpunkt der Thrombozytenaggregationshemmer.

Nachdem ASS seit langem den Therapiestandard darstellt, haben Thienopyridine und Glykoprotein-IIb/IIIa-Rezeptorantagonisten in den letzten Jahren bei bestimmten Indikationen zunehmend an Bedeutung gewonnen. Wegen der neuen Definition des akuten Koronarsyndroms und wegen der Ergebnisse neuerer, sehr großer Therapiestudien haben alle großen kardiologischen Gesellschaften ihre Leitlinien aktualisiert. Im Folgenden soll der Stellenwert der Thrombozytenaggregationshemmung bei der Therapie von verschiedenen Manifestationen der KHK aufgezeigt werden.

Literatur

  • 1 Carlo Patrono C, Coller B, Dalen J E, FitzGerald G A. et al . Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects.  CHEST. 2001;  119 39S-63S
    CrossrefPubMedGoogle Scholar
  • 2 Kallmann R, Nieuwenhuis H K, de Groot P G. et al . Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-Keto-PGF1a excretion in healthy subjects.  Thromb Res. 1987;  45 355-361
    CrossrefPubMedGoogle Scholar
  • 3 Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
    PubMedGoogle Scholar
  • 4 Valles J, Santos M T, Aznar J. et al . Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity.  Circulation. 1998;  97 350-355
    PubMedGoogle Scholar
  • 5 Ridker P M, Cushman M. Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med. 1997;  336 973-979
    CrossrefPubMedGoogle Scholar
  • 6 Jarvis B, Simpson K. Clopidogrel - a review of its use in the prevention of atherothrombosis.  Drugs. 2000;  60 347-377
    CrossrefPubMedGoogle Scholar
  • 7 McTavish D, Faulds D, Goa K L. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.  Drugs. 1990;  40 238-259
    PubMedGoogle Scholar
  • 8 Caplain H, D’Honneur G, Cariou R. Lack of interaction of aspirin (1000 mg) with chronic clopidogrel in volunteers.  Haemostasis. 1996;  26 (Suppl 3) abstract no 557
    PubMedGoogle Scholar
  • 9 Moshfegh K, Redondo M, Julmy F. et al . Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction.  J Am Coll Cardiol. 2000;  36 699-705
    CrossrefPubMedGoogle Scholar
  • 10 Auer J, Berent R, Laßnig E. et al . Thrombozytäre Glykoprotein-IIb/IIIa-Rezeptor-Blocker in der Behandlung der koronaren Herzkrankheit.  Herz. 2003;  28 393-403
    PubMedGoogle Scholar
  • 11 Sanmuganathan P S, Ghahramani P, Jackson P R. et al . Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.  Heart. 2001;  85 265-271
    CrossrefPubMedGoogle Scholar
  • 12 Harrington R A, Becker R C, Ezekowitz M. et al . Antithrombotic therapy for coronary artery disease. The seventh ACCP Conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126 513S-548S
    CrossrefPubMedGoogle Scholar
  • 13 Juul-Möller S, Edvardsson N, Jahmatz B. et al . Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Swedish angina pectoris aspirin trial (SAPAT).  Lancet. 1992;  340 1421-1425
    CrossrefPubMedGoogle Scholar
  • 14 Ridker P M, Manson J E, Gaziano M. et al . Low-dose aspirin therapy for chronic stable angina: a randomised, placebo-controlled clinical trial.  Ann Intern Med. 1991;  114 835-839
    PubMedGoogle Scholar
  • 15 Antiplatelet Trialists’ Collaboration . Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
    PubMedGoogle Scholar
  • 16 Dietz R, Rauch B. Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung (DGK).  Z Kardiol. 2003;  92 501-521
    PubMedGoogle Scholar
  • 17 CAPRIE . A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events.  Lancet. 1996;  348 1329-1339
    CrossrefPubMedGoogle Scholar
  • 18 Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D. et al . European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.  Eur Heart J. 2004;  25 (2) 166-181
    CrossrefPubMedGoogle Scholar
  • 19 Antithrombotic Trial Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
    CrossrefPubMedGoogle Scholar
  • 20 Hamm C W. Leitlinien: Akutes Koronarsyndrom (ACS) Teil 1: ACS ohne persistierende ST-Hebung.  Z Kardiol. 2004;  93 72-90
    CrossrefPubMedGoogle Scholar
  • 21 The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators . Effects of Clopidogrel in addition to Aspirin in patients with Acute Coronary Syndromes without ST-Segment Elevation.  N Engl J Med. 2001;  345 494-502
    CrossrefPubMedGoogle Scholar
  • 22 ISIS-2 Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction.  Lancet. 1988;  2 349-360
    PubMedGoogle Scholar
  • 23 Sabatine M S, Cannon C P, Gibson C M. et al . Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation.  N Engl J Med. 2005;  352 1179-1189
    CrossrefPubMedGoogle Scholar
  • 24 Doson C, Christopher L, Babor E-M. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction. Letter to the Editor.  N Engl J Med. 2005;  352 2647-2648
    CrossrefPubMedGoogle Scholar
  • 25 Hamm C W. Leitlinien: Akutes Koronarsyndrom (ACS) Teil 2: ACS mit persistierender ST-Hebung.  Z Kardiol. 2004;  93 324-341
    CrossrefPubMedGoogle Scholar
  • 26 The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology . Guidelines for Percutaneous Coronary Interventions.  European Heart Journal. 2005;  26 804-807
    CrossrefPubMedGoogle Scholar
  • 27 Urban P, Macaya C, Rupprecht H J. et al . Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).  Circulation. 1998;  98 2126-2132
    PubMedGoogle Scholar
  • 28 Bertrand M E, Rupprecht H, Urban P. et al . Clopidogrel aspirin stent international cooperative study. CLASSICS.  Circulation. 2000;  102 624-629
    PubMedGoogle Scholar
  • 29 Silber S, Albertsson P, Aviles F F, Camici P G, Colombo A, Hamm C, Jorgensen E. et al . Task Force Members. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology.  Eur Heart J. 2005;  26 (8) 804-847
    CrossrefPubMedGoogle Scholar
  • 30 Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease.  N Engl J Med. 1974;  290 1158-1162
    PubMedGoogle Scholar
  • 31 Derry S, Loke Y K. Risk of gastrointestinal hemorrhage with long term use of aspirin: Meta-analysis.  Br Med J. 2000;  321 1183-1187
    CrossrefPubMedGoogle Scholar
  • 32 He J, Whelton P K, Vu B. et al . Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomised controlled trials.  JAMA. 1998;  280 1930-1935
    CrossrefPubMedGoogle Scholar
  • 33 Hankey G J, Sudlow C LM, Dunbabin D W. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.  Stroke. 2000;  31 1779-1784
    PubMedGoogle Scholar
  • 34 Bennett C L, Connors J M, Carwile J M. et al . Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342 1773-1777
    CrossrefPubMedGoogle Scholar
  • 35 The EPIC Investigators . Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.  N Engl J Med. 1994;  330 956-961
    CrossrefPubMedGoogle Scholar
  • 36 Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs.  J Thromb Haemost. 2003;  1 1710-1713
    CrossrefPubMedGoogle Scholar
  • 37 Geiger J, Teichmann L, Grossmann R. et al . Monitoring of Clopidogrel Action: Comparison of Methods.  Clinical Chemistry. 2005;  51(6) 957-965
    CrossrefPubMedGoogle Scholar
  • 38 Grotemeyer K H, Scharafinski H W, Husstedt I W. Two year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 poststroke patients.  Thromb Res. 1993;  71 397-403
    CrossrefPubMedGoogle Scholar
  • 39 Gum P A, Kottke-Marchant K, Welsh P A, White J, Topol E J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.  J Am Coll Cardiol. 2003;  41 961-965
    CrossrefPubMedGoogle Scholar
  • 40 Barragan B, Bouvier J-L, Roquebert P-O, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation.  Cathet Cardiovasc Intervent. 2003;  59 295-302
    CrossrefPubMedGoogle Scholar

Dr. med. Felix Post

II. Medizinische Klinik und Poliklinik

Klinikum der Johannes Gutenberg-Universität · Langenbeckstr. 1 · 55131 Mainz

Email: post@2-med.klinik.uni-mainz.de

      >